Marc-Andre Cornier, MD, professor and director of the Division of Endocrinology, Diabetes and Metabolic Diseases at the Medical University of South Carolina, describes the genetic factor that contributes to obesity risk.
Although individuals can't alter their genetics, they can alter their environment, said Marc-Andre Cornier, MD, endocrinologist, professor, and director of the Division of Endocrinology, Diabetes and Metabolic Diseases at the Medical University of South Carolina.
Transcript
What does it mean to be prone to obesity?
We believe that there's a genetic component to the risk for obesity. The way to think about it is the opposite. There are people in our environment who are lean, normal weight, thin, and there's very strong genetics for that as well. And so it's our belief that people are either prone to weight gain or not, and in the right environment, that leads to weight gain and obesity. So that might be, you know, differences in physiologic markers that relate to body weight regulation; it could be differences in signaling in the brain.
There's not one specific thing that says this is what makes the person prone to to gain weight. But we clearly see familial patterns to this. There's clearly genetic components to the risk for obesity. And so we like to think about it as potential proneness or genetic risk. Can you alter that? Yes, by altering the environment. You can't change genetics, you can't change your own baseline physiology, but you can change your environment and that's what we have to work on.
BCI Shows Promise of Personalized Endocrine Therapy in Breast Cancer
January 15th 2025The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially lower health care costs.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Designing Care for the Underserved Creates Higher-Value Health Solutions
January 12th 2025In the second half of our interview with Brita Roy, MD, MPH, MHS, NYU Grossman School of Medicine, she discusses effective engagement of minoritized populations in discussion of medical mistrust.
Read More
AI's Role in Oncology: Supporting, Not Replacing, Health Care Providers
January 9th 2025In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he discusses opportunities for advancing the smart use of artificial intelligence (AI) in cancer care.
Read More